Gastroenterology, Hepatology & Digestive Disorders

Gastroenterology, Hepatology & Digestive Disorders

Open Access
ISSN: 2639-9334
Original Research Article

Quality of Follow-up of Chronic Hepatitis B Patients in Two Confessional Hospitals in Ouagadougou (Burkina Faso): Retrospective Cohort Study from 2009 to 2022

Authors: Guingané Alice Nanelin, Motoula Latou Peres Mardochée, Zoure Nogogna, Pakmoagda Emmanuel Parfait, Santi Saidou, Kontiebo Jonathan, Sawadogo Lydie, Zoungrana S Léonce, Soudré/Héma Sandrine, Coulibaly Aboubacar, Sawadogo Appolinaire, Bougouma Alain.

DOI: 10.33425/2639-9334.1123


Abstract

Introduction: Chronic hepatitis B is a major public health problem in Burkina Faso, where the prevalence of HBs antigen is estimated at 9.1% in the general population [3]. Long and costly clinical and biological monitoring is often the responsibility of patients and must therefore be thorough to prevent complications such as cirrhosis and hepatocellular carcinoma (HCC), but also to avoid unnecessary expenses that could lead to patients dropping out of follow-up. This study aimed to evaluate the quality of care for patients with chronic hepatitis B in two faith-based referral hospitals in Ouagadougou.

Methods: A retrospective cohort study was conducted from January 1, 2009, to April 24, 2022, at Schiphra Protestant Hospital and Saint Camille Hospital (HOSCO). All patients aged at least 18 years, carriers of HBs antigen for more than 6 months, were included through exhaustive recruitment. Patient follow-up was carried out through semi-annual visits. A descriptive analysis allowed us to outline the biochemical and virological responses, as well as the progression of fibrosis in these patients, along with the occurrence of evolving complications. Eligibility for antiviral treatment was assessed using an APRI score > 2, the 2025 European Association for the Study of the Liver (EASL) guidelines, and the 2024 WHO recommendations to highlight the existing differences. The quality of follow-up was evaluated over a two-year period covering 5 visits (Day 0, Month  6, Month 12, Month 18, Month 24) and was based on the regularity of check-ups, patient eligibility for treatment according to the 2024 WHO guidelines, and retention in care.

Results: In total, 355 patients were included with an average age of 33.6 ± 10.4 years; the M/F sex ratio was 1.3, and the average follow-up duration was 29.4 months. Patients who had at least 3 visits out of the 5 planned over 24 months were considered to have regular follow-up and represented 25.6% of the patients. While transaminases and ultrasound were performed in 100% of cases at inclusion, the rates of testing for HBV DNA (86%), blood count (47%), creatinine (38.6%), alpha-fetoprotein (28.7%), and albumin (4.7%) remained insufficient. Eligibility for treatment varied considerably: 3.7% according to APRI > 2, 29.3% according to EASL 2025, and 39.2% according to WHO 2024. Overall, 173 patients (48.7%) were treated with ténofovir disoproxil fumarate (TDF). Complete virologic response increased from 46.2% at 12 months to 63.1% at 24 months. Fibrosis regression was observed in 51.1% of treated patients. At the end of the follow-up, we found 4.8% of the patients with cirrhosis and  3.1% with primary liver cancers (PLC). 

View / Download PDF
Citation: Guingané Alice Nanelin, Motoula Latou Peres Mardochée, Zoure Nogogna, et al. Quality of Follow-up of Chronic Hepatitis B Patients in Two Confessional Hospitals in Ouagadougou (Burkina Faso): Retrospective Cohort Study from 2009 to 2022. Gastroint Hepatol Dig Dis. 2026; 9(4). DOI: 10.33425/2639-9334.1123
Editor-in-Chief
Elisa Gravito Soares MF
Elisa Gravito Soares MF
Department of Gastroenterology | Coimbra University Hospital

View full editorial board →
Journal Metrics
Impact Factor 2.65*
Acceptance Rate 75%
Time to first decision 6 -10 Days
Submission to acceptance 12-15 Days